Down to Earth: What Gardening and Allotments Are Teaching the Life Sciences Sector

Across the UK, well over 100,000 people are currently on a waiting list for an allotment, with an average wait of around four years before a plot becomes free. That level of sustained demand for a patch of soil and a shed is unusual enough to be worth asking why, and life sciences research is starting to offer some genuine answers. A national evaluation of gardening as a form of NHS-linked treatment has found wellbeing improvements that stand up to statistical scrutiny. Soil scientists are trying to close a widening gap between what laboratories know about the organisms living in soil and what the people actually growing food in it believe. And decades-old work on soil bacteria and mood is still shaping how researchers think about the mechanism behind it all. Gardening did not need life sciences to make it worthwhile, but life sciences is increasingly interested in why it works.

A Waiting List Nearly Four Years Long

An analysis of Freedom of Information responses from 175 local councils across the UK, published in 2025, found 108,958 people waiting for an allotment plot, with an average wait time of around four years. It is one of several recent counts of allotment demand, and the exact totals vary a little depending on which councils respond and when the count is taken, but every version of the exercise tells the same basic story of demand that has outpaced supply for years. The picture varies sharply by area. The South East accounts for the largest single share, with almost 21,000 people waiting, while councils including West Dunbartonshire and the London Borough of Haringey report average waits of nine years. Several other councils, among them Lewisham, Bolsover and East Riding, sit at around eight years.

Numbers like these are not, on their own, evidence of anything beyond demand outstripping supply, but they set the scale for everything that follows. This is not a niche hobby with a small, dedicated following. It is a form of activity that hundreds of thousands of people are prepared to wait years for, at a time when councils have limited land and limited budgets to expand provision. That gap between appetite and access is precisely what has made gardening and food growing an attractive target for researchers asking whether the wellbeing benefits people report anecdotally can actually be measured.

What Green Prescribing Actually Measured

Green social prescribing, referring GPs to nature-based activities rather than, or alongside, medication, has been running as a formal test-and-learn programme across seven sites in England, coordinated with DEFRA. An evaluation published in May 2025 by the NIHR’s Applied Research Collaboration for Yorkshire and Humber looked at more than 200 participants with mental health problems who took part in one of three categories of activity: horticulture and care farming, sport and physical activity, or creative and other outdoor-based activities, tracked using the ONS-4 wellbeing measure and the Hospital Anxiety and Depression Scale before and after their involvement.

The results showed statistically significant improvements in life satisfaction, happiness and a sense that life was worthwhile, alongside reductions in anxiety and depression symptoms. Two patterns stood out. Longer engagement mattered: people who took part for nine weeks or more saw stronger effects than those who took part for four weeks or fewer. And horticulture and care farming, the category that includes allotment and community gardening work, produced the strongest results of the three activity types. The researchers noted that the size of the effect on anxiety and depression was comparable to what is typically seen with established primary care treatments such as cognitive behavioural therapy, a striking claim for an intervention that mostly consists of digging, weeding and growing food.

The Gap Between the Lab and the Allotment

The wellbeing case for gardening has a plausible biological starting point in research that is now nearly two decades old. In 2007, researchers at the University of Bristol and University College London found that Mycobacterium vaccae, a harmless bacterium commonly found in soil, activated serotonin-producing neurons in mice in a pattern similar to that seen with antidepressant drugs. The work began from an unexpected clinical observation: cancer patients treated with the bacterium in an earlier trial had reported an improved quality of life that could not be explained by their cancer treatment alone. It is a mouse study of a specific bacterium, not direct proof that turning over soil in an allotment produces the same effect in a human brain, but it gives researchers a concrete mechanism worth testing rather than a vague appeal to fresh air.

More recent work has shifted from mechanism to practice. A 2026 study from the University of Sheffield’s Department of Animal and Plant Sciences, based on interviews with UK growers, examined how farmers and gardeners actually understand and manage the soil microbiome, and how they view commercial soil inoculant products designed to boost it. The researchers found a wide gap between the science of microbial inoculants and how growers actually use, or ignore, that science, with most relying instead on experiential knowledge built up over years of working the same ground. Their recommendation was that future product development should involve growers directly, rather than treating soil science as something to be handed down finished. It is a useful corrective to any assumption that the people on allotment waiting lists are simply waiting for scientists to tell them what to do. In practice, a lot of the working knowledge about soil already sits with them.

Why the Life Sciences Keep Digging Here

None of these three threads, the size of the waiting list, the wellbeing data and the soil science, would carry much weight alone. Together they describe something more specific: an activity that huge numbers of people already value enough to wait years for, that formal healthcare evaluation is now able to measure with the same tools used to judge conventional treatment, and that still has real gaps between what the laboratory understands and what the person with the trowel understands. Allotments and gardens were never going to need a research paper to justify themselves to the people already queuing for a plot. What is changing is how much of that value the life sciences can now actually demonstrate, measure and explain.

Sources: Freedom of Information data on UK council allotment waiting lists (2025); NIHR Applied Research Collaboration Yorkshire and Humber; DEFRA green social prescribing programme; University of Bristol; University of Sheffield.

Author

Leave A Comment

Graham Combe

Strategic Consultant,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Graham Combe is an experienced strategic consultant, relationship builder, and entrepreneur in the global life sciences sector. He holds a BSc (Hons) in Chemistry from University College London (UCL) and spent over a decade with Nature, where he pioneered key initiatives such as Nature’s BioPharma Dealmakers and Nature’s SciCafe.

In May 2011, he founded Biosell UK, a consulting and event management firm that collaborates with global life science publishers, event organizations, and marketing partners. Beyond BioSell, Combe is the founder or co-founder of several prominent networking and thought-leadership platforms, including #BiotechBuddies, #coffeebuddies, the #AgileLeaders Forum, and the Creative Disruption Forum—the latter three events co-hosted with his business partner, Professor Tony Sedgwick.

Specializing in the early-to-mid stages of drug development (from pre-clinical research through Phase 3 and clinical proof-of-concept), Graham focuses on facilitating forums to promote peer-to-peer discussion, strategic growth, investment and meaningful connections between biotech innovators, investors, and industry service providers.

Apply for a complimentary Conference Day VIP Pass

Apply for a complimentary Conference Day VIP Pass

Complimentary Conference Day VIP Passes are reserved for senior leaders and decision-makers with influence over purchasing, commissioning, investment or technology advancements and adoption across UK life sciences.

A Conference Day VIP Pass includes:

  • Complimentary access-all-areas to the Launch Day Conference
  • Access to the dedicated VIP green room alongside Conference speakers
  • Access to all general keynote, panel and programme sessions
  • Curated networking opportunities
  • Opportunities to meet conference speakers and other approved VIP attendees

The VIP Pass applies to the Launch Day Conference only. It does not include admission to the Life Sciences Week Gala Dinner or other separately ticketed events.

Applications are reviewed individually and submitting this form does not guarantee a complimentary pass. To maintain a balanced, high-quality audience, we may limit the number of VIP Passes issued to any one organisation.

    First Name *

    Last Name *

    Work Email Address *

    Telephone Number *

    Job Title *

    Organisation *

    LinkedIn

    Organisation Information

    Which best describes your organisation? *


    If other, please specify

    Which best describes your level of seniority? *

    If other, please specify

    Which areas are you responsible for or directly involved in? *

    If other, please specify

    What best describes your role in purchasing, investment, commissioning or adoption decisions? *

    Attendance Information

    Briefly, what is the number one thing you are hoping to get out of attending Life Sciences Week 2026? *

    Final Confirmation

    Is your role primarily focused on selling products or services, consultancy, account management or business development? *

    Please Confirm *

    I understand that VIP applications are subject to review and approval.
    I understand that the complimentary VIP Pass covers the Life Sciences Week Launch Day Conference only and does not include the Gala Dinner Awards or other separately ticketed events.
    The information supplied in this application is accurate.

    Shabna Raja

    Advisory Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Shabna Raja is a senior leader in enterprise transformation within Life Sciences, with over 20 years’ experience spanning pharma, consumer health and large-scale digital programmes.

    She specialises in bridging strategy and execution – helping organisations translate AI, data and digital innovation into tangible business outcomes. Her work focuses on complex transformation
    initiatives across commercial, data and operating model domains within regulated environments.

    Shabna spent seven years at GSK, where she played a key role in transformation programmes, including as part of the Consumer Health joint venture with Pfizer — one of the most significant integrations in the sector. This experience provided her with deep expertise in  organisational change, integration and operating model evolution at global scale.

    More recently, she has spent over three years working closely with Haleon through a strategic
    services partnership, leading enterprise client engagement and managing a multi-million-pound account while supporting transformation across a newly independent global organisation.

    Her experience spans the end-to-end life sciences value chain, including R&D, commercial, supply chain and patient engagement, giving her a holistic perspective on how technology and transformation can unlock value across the industry.

    Amjad Khan

    Executive Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Amjad Khan is a UK-based entrepreneur, AI strategist, and senior technology leader with over 15 years of experience at Pfizer, where he held multiple leadership roles across digital strategy and transformation. As Global Digital Client Partner, he was responsible for digital strategy and execution across Global Business Units covering Vaccines, Hospital, and Medical Affairs. Most notably, he led the commercial launch for the Covid franchise transforming and accelerating the model for how new medicines are brought to market.

    Following his tenure at Pfizer, Amjad channelled his expertise into building at the frontier of AI. His work spans AI leadership, stakeholder engagement, and agile delivery helping organisations adopt and scale emerging  technologies to drive meaningful outcomes.

    Dr. Richard Fallon | Business Consultant | WM Life Sciences

    Dr. Richard Fallon

    Co Founder, Life Sciences Week 
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Dr Richard Fallon is an entrepreneur and ecosystem builder who connects industry leaders, investors and public-sector stakeholders to accelerate collaboration and commercial growth.

    As the Founder of the Technology Supply Chain and co-founder of the Innovation Awards, he has spent more than two decades convening influential networks that help emerging businesses find capital, strategic partners and new routes to market.

    Richard’s work spans leadership and consultancy across major organisations, alongside building membership and partnership platforms that bring universities, industry and investors into the same room – and turn conversations into practical outcomes.

    With his focus on life sciences, Richard supports organisations and people driving breakthroughs in healthcare, biotechnology, medical technology and advanced research. He is passionate about creating the conditions for transformative ideas to move from concept to real-world impact – by connecting innovators with the funding, expertise and opportunities they need to scale.

    Through Life Sciences Week, Richard is championing the UK’s world-class life sciences community and helping position it at the forefront of innovation, investment and patient outcomes.

    Amy Deakin | Chief of Staff | WM Life Sciences

    Amy Deakin

    Event Managing Director,
    Life Sciences Week
    +44 (0) 121 227 4156
    info@lifesciencesweek.co.uk

    Bio

    Amy Deakin is a Birmingham-based leader specialising in building partnerships and fostering innovation in the life sciences sector. With a degree in Sport and Exercise Science, Amy brings a grounded understanding of human health and performance to her work and a strong interest in the developments shaping healthcare today.

    Amy is Managing Director of Life Sciences Week, part of the One Thousand Trades Group, and also serves as Director of One Thousand Trades Events. In these roles, she convenes researchers, clinicians and industry leaders to strengthen collaboration, unlock new partnerships and help accelerate real-world innovation across the life sciences ecosystem.

    Her career spans both commercial and third-sector environments. She began in automotive design, delivering projects for Volkswagen, McLaren, Bentley and Jaguar Land Rover, before moving into the third sector with Acorns Children’s Hospice. She later joined Western Union, working as a Partnerships Manager for international payments

    An avid netballer, Amy is a committed advocate for health and wellbeing – bringing energy, clarity and connection to everything she builds, and actively involved as a participant in health related research studies.

      Award Category Voting

      Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

      Day you've not voted in, will be denoted with an ❌

      If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

      Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

      Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

      No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

      Awarding an individual or organisation for exceptional long-term impact on the industry.

      No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

      Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

      No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

      Your Details